Ambrisentan therapy in pulmonary hypertension: oedema is the most common side effect leading to cessation of therapy
Ambrisentan ( US: Letairis; EU: Volibris ) is an oral selective endothelin receptor antagonist licensed for use in pulmonary arterial... ...
read